197 related articles for article (PubMed ID: 8175352)
1. [Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Second comment].
Gefeller O; Kleeberg U; Kölmel KF
Hautarzt; 1994 Mar; 45(3):191-2; author reply 193-4. PubMed ID: 8175352
[No Abstract] [Full Text] [Related]
2. [Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. First comment].
Windeler J; Lange S; Trampisch HJ
Hautarzt; 1994 Mar; 45(3):189-90; author reply 193-4. PubMed ID: 8175351
[No Abstract] [Full Text] [Related]
3. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
[TBL] [Abstract][Full Text] [Related]
4. [Interferon therapy in malignant melanoma].
Kokoschka EM; Micksche M
Wien Med Wochenschr; 1993; 143(16-17):441-2. PubMed ID: 8273369
[TBL] [Abstract][Full Text] [Related]
5. [The adjuvant therapy of malignant melanoma].
Hauschild A; Sterry W
Dtsch Med Wochenschr; 1992 Feb; 117(8):303-6. PubMed ID: 1537268
[No Abstract] [Full Text] [Related]
6. [Adjuvant and palliative therapy of melanoma. Current status].
Tilgen W
Chirurg; 1994 Mar; 65(3):153-63. PubMed ID: 7514966
[TBL] [Abstract][Full Text] [Related]
7. [Consensus conference. Follow-up of patients surgically treated for stage I melanoma].
Ann Dermatol Venereol; 1995; 122(5):250-8. PubMed ID: 8572461
[No Abstract] [Full Text] [Related]
8. Malignant melanoma.
Califano J; Nance M
Facial Plast Surg Clin North Am; 2009 Aug; 17(3):337-48. PubMed ID: 19698915
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary treatment of primary melanoma.
Yao K; Balch G; Winchester DJ
Surg Clin North Am; 2009 Feb; 89(1):267-81, xi. PubMed ID: 19186240
[TBL] [Abstract][Full Text] [Related]
10. [Comment on the contribution by G. Fierlbeck, B. d'Hoedt, W. Stroebel, H. Stutte, O. Bogenschütz and G. Rassner. Intralesional therapy of melanoma metastases with recombinant interferon-beta].
Kölmel KF; Abel U
Hautarzt; 1993 May; 44(5):329-30. PubMed ID: 8320124
[No Abstract] [Full Text] [Related]
11. [Prognostic factors and improving treatment of cutaneous melanoma].
Vihinen P; Kähäri VM; Pyrhönen S
Duodecim; 2004; 120(12):1445-56. PubMed ID: 15293705
[No Abstract] [Full Text] [Related]
12. Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients.
Gimotty PA; Guerry D; Flaherty K
J Clin Oncol; 2008 Feb; 26(4):517-8. PubMed ID: 18235111
[No Abstract] [Full Text] [Related]
13. [Comment on the contribution by C. Garbe et al.: Combination of interferon-alpha with cytostatic drugs: promising therapeutic approach in metastatic melanoma].
Kleeberg UR; Kölmel KF
Hautarzt; 1992 Nov; 43(11):737-8. PubMed ID: 1468937
[No Abstract] [Full Text] [Related]
14. [Diagnosis and treatment of malignant melanoma of the skin (a lecture)].
Denisov LE; Kurdina MI
Khirurgiia (Mosk); 1996; (1):17-22. PubMed ID: 8683912
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group].
Hauschild A; Dummer R; Garbe C; Kaufmann R; Schadendorf D; Soyer HP; Stadler R; Tilgen W
Hautarzt; 1998 Mar; 49(3):167-9. PubMed ID: 9565782
[No Abstract] [Full Text] [Related]
16. [Adjuvant therapy of malignant melanoma].
Hauschild A; Volkenandt M
Ther Umsch; 1999 Jun; 56(6):324-9. PubMed ID: 10420815
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis, treatment and follow-up of primary malignant skin melanoma].
Ketterer R
Rev Med Suisse Romande; 1995 Oct; 115(10):753-7. PubMed ID: 7501925
[No Abstract] [Full Text] [Related]
18. [Therapeutic manual of malignant melanoma].
Moroi Y
Fukuoka Igaku Zasshi; 2009 Feb; 100(2):51-8. PubMed ID: 19455975
[No Abstract] [Full Text] [Related]
19. Cutaneous melanoma: detecting it earlier, weighing management options.
Lane JE; Dalton RR; Sangueza OP
J Fam Pract; 2007 Jan; 56(1):18-28. PubMed ID: 17217894
[No Abstract] [Full Text] [Related]
20. Higher serum 25-hydroxy vitamin D3 levels at presentation are associated with improved survival from melanoma, but there is no evidence that later prevailing levels are protective.
Hutchinson PE; Osborne JE; Pringle JH
J Clin Oncol; 2010 Sep; 28(27):e492-3; author reply 494-5. PubMed ID: 20625133
[No Abstract] [Full Text] [Related]
[Next] [New Search]
